From Seattle, Washington, USA:
Apidra is the newest insulin analog to be available in the U.S. shortly. It is manufactured by Sanofi-Aventis, the same group which produces Lantus. It is insulin glulisine. The metabolic profile is similar to NovoLog and Humalog. It is approved for pump use and will be available in a pen system.
A number of my patients are anxious to try the new analog to see if there is a difference. After reading the literature available, particularly in the European sector, I do not think there will be much of a difference in activity, but each individual may find one of the analogs better for him/her. I would use the one that is most comfortable for you.
Additional comments from Jane Seley, diabetes nurse specialist:Apidra is a rapid acting insulin analog, as are Humalog and NovoLog. Apidra has approval by the FDA to be injected anywhere from 15 minutes before a meal to 20 minutes after starting a meal. In reality, Humalog and NovoLog could also be injected within 15 to 20 after eating, but there is no FDA approval to do so. I do want to emphasize that, ordinarily, you do not want to inject after eating, the delay could cause an unnecessary rise in blood sugar. It may be helpful to inject after if you aren't sure how much you are going to be able to eat (maybe you feel sick) or your sugar is very low before the meal. Once Apidra becomes readily available in the U.S., we will be able to see how it compares to NovoLog and Humalog.
Original posting 28 Feb 2005
Posted to Insulin Analogs
Last Updated: Tuesday April 06, 2010 15:09:59
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by Children With Diabetes, Inc, which is responsible for its contents.
© Children with Diabetes, Inc. 1995-2014. Comments and Feedback.